Request Demo

Last update 24 Mar 2026

Abatacept

Last update 24 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Fc fusion protein

Synonyms

Abatacept (Genetical Recombination), CTLA4-Ig(Bristol-Myers Squibb), CTLA4Ig

+ [14]

Target

CD80 x CD86

Action

modulators

Mechanism

CD80 modulators(Cluster of differentiation 80 modulators), CD86 modulators(Cluster of differentiation 86 modulators)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesSkin and Musculoskeletal Diseases+ [4]

Active Indication

Acute Graft Versus Host DiseaseJuvenile Idiopathic ArthritisArthritis, Psoriatic+ [8]

Inactive Indication

acute leukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+ [64]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Baker Heart & Diabetes Institute

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIG

+ [3]

Inactive Organization

Bristol-Myers Squibb GmbH & Co. KGaA

Jiangsu Simcere Pharmaceutical Co., Ltd.

License Organization

Repligen Corp.

Ono Pharmaceutical Co., Ltd.

Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (23 Dec 2005),

Rheumatoid Arthritis

RegulationOrphan Drug (United States)

Structure/Sequence

Sequence Code 19593

Source: *****

238

Clinical Trials associated with Abatacept

NCT07388563

/ RecruitingPhase 1IIT

A Phase I Trial of Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Background:
T-cell lymphoma is a blood cancer that affects immune system cells. People tend to survive less than 1 year if this disease does not respond to treatment (is refractory) or comes back after treatment (relapses). Azacitidine and abatacept are 2 drugs that are used to treat other diseases. Researchers want to know if these drugs, used together, can help people with T-cell lymphoma.
Objective:
To learn if azacitidine combined with abatacept can shrink tumors in people with T-cell lymphoma.
Eligibility:
People aged 18 years and older with T-cell lymphoma that either came back or did not respond to treatment.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. They will have imaging scans of their tumors. A sample of tumor tissue may be taken.
Azacitidine is injected under the skin of the thigh, abdomen, or upper arm. Abatacept is infused through a needle inserted into a vein in the arm.
Participants will receive the study drugs in 28-day cycles for up to 13 cycles. They will come to the clinic for each treatment. They will come to the clinic on day 1 and day 15 of the first cycle. After that, they will come to the clinic on the first 5 or 7 days of each cycle. Each clinic visit will take no more than 8 hours.
Imaging scans and other tests will be repeated during the study. Participants will have follow-up visits for up to 5 years after they stop taking the study drugs....

Start Date26 Mar 2026

Sponsor / Collaborator

National Cancer Institute

NCT06654882

/ RecruitingPhase 3IIT

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

Start Date09 Jan 2026

Sponsor / Collaborator

Duke University

[+1]

NCT06731504

/ RecruitingEarly Phase 1IIT

A Pilot Trial of Abatacept Based Graft-Versus-Host Disease Prophylaxis Following Omidubicel Hematopoietic Cell Transplantation

This study is a single-center, non-randomized, single-arm pilot trial of omidubicel hematopoietic stem cell transplantation (HCT) for hematologic malignancies with myeloablative conditioning chemotherapy of physician's choice followed by abatacept/tacrolimus/mycophenolate mofetil (ABA/Tac/MMF) graft-versus-host disease (GVHD) prophylaxis. The primary objective is to assess the safety and feasibility of abatacept/tacrolimus/mycophenolate mofetil GVHD prophylaxis following omidubicel HCT.
Target enrollment is 10 participants. Subjects are adults with a diagnosis of hematologic malignancy with an available cord blood unit for omidubicel product manufacturing. Patients will be followed for a total of 18 months and will have research blood draws and Abatacept pharmacokinetics, as well as standard of care assessments that will be reviewed for this study.
It is estimated that 36 months of accrual will be necessary to enroll the targeted sample size with an accrual rate of approximately 1 participant every 3 months. Accrual will be reported by race, ethnicity, gender, and age. Descriptive analyses are planned given the sample size.

Start Date12 Nov 2025

Sponsor / Collaborator

Duke University

100 Clinical Results associated with Abatacept

100 Translational Medicine associated with Abatacept

100 Patents (Medical) associated with Abatacept

2,945

Literatures (Medical) associated with Abatacept

01 Apr 2026·SEMINARS IN ARTHRITIS AND RHEUMATISM

Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials

Article

Author: Huizinga, T W J ; Niemantsverdriet, E ; Verstappen, M ; van der Helm-van Mil, A H M ; Bergstra, S A

OBJECTIVE:

To predict which early RA-patients achieve clinical remission on initial treatment with methotrexate monotherapy or with abatacept+methotrexate.

METHODS:

This study is a subanalysis of the AVERT and AVERT-2 randomized controlled trials, which were performed in ACPA-positive early RA-patients who received methotrexate monotherapy or abatacept + methotrexate. External model validation of patients on methotrexate monotherapy was performed in the observational Leiden Early Arthritis Clinic (EAC) cohort. Primary outcome was DAS28-CRP remission at 6 and 12 months follow-up. Prediction models were developed using logistic regression analysis. First, a model including clinical baseline variables only was estimated. Subsequently, it was assessed whether adding serological or imaging data, shared epitope or early DAS28 response improved model performance.

RESULTS:

In the methotrexate-monotherapy group (n=388), 27% and 39% of patients achieved DAS28-remission after 6 and 12-months. In the abatacept + methotrexate group (n=743) this was 43% and 53%. Baseline DAS28-CRP was predictive for clinical remission in all models. Optimism-adjusted model performance (AUROC) for DAS28-remission at 6 and 12-months was 0.66/0.65 in the methotrexate-group and 0.68/0.59 in the abatacept + methotrexate group. Adding baseline MRI-detected joint-inflammation, baseline serology or HLA-shared epitope alleles did not significantly improve model performance. Early DAS28-response did improve model performance. In the external validation cohort model performance was very similar.

CONCLUSION:

Determining which patients achieve clinical remission upon methotrexate or abatacept+methotrexate treatment remains challenging. Disease activity at disease presentation and early DAS response were the only consistent predictors for achieving clinical remission. Genetic, imaging and serology parameters did not improve model performance.

01 Apr 2026·SEMINARS IN ARTHRITIS AND RHEUMATISM

Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD

Article

Author: Lee, Bora ; Kim, Hyun-Sook ; Lee, Kyung-Ann

OBJECTIVES:

To evaluate the risk of interstitial lung disease (ILD) and safety outcomes of disease-modifying antirheumatic drug (DMARD) classes in rheumatoid arthritis (RA), focusing on patients with RA-associated ILD (RA-ILD).

METHODS:

We conducted a nationwide cohort study using Korean National Health Insurance Service data (2011-2020). Adults with newly diagnosed RA prescribed at least one csDMARD were included and followed until 2022. Four treatment groups were evaluated: TNFi, non-TNFi biologics (abatacept, rituximab, tocilizumab), JAKi, and csDMARDs. RA-ILD was defined as ≥2 ILD claims plus chest computed tomography confirmation. Outcomes included ILD incidence, hospitalisation, infection, MACE, and all-cause mortality. Time-varying Cox models with inverse probability of treatment weighting were applied for first-event analyses.

RESULTS:

We analysed 26,120 patients with RA (209,852 treatment episodes), including 641 RA-ILD patients (1688 episodes). Adjusted ILD incidence was similar across DMARD classes. In RA and RA-ILD, non-TNFi biologics were associated with higher risks of hospitalisation (RA aHR 1.30, 95% CI 1.21-1.40; RA-ILD 1.35, 1.02-1.80), infection (RA 1.16, 1.05-1.28; RA-ILD 1.51, 1.06-2.15), and mortality (RA 4.09, 3.04-5.50; RA-ILD 4.31, 2.21-8.41) compared with csDMARDs. ILD-related admissions were similar, but pneumonia-related hospitalisations and recurrences were higher with non-TNFi biologics. TNFi and JAKi showed no significant associations with hospitalisation or infection. MACE risk did not differ across groups.

CONCLUSIONS:

DMARD class was not associated with ILD incidence or ILD-related hospitalisation. Non-TNFi biologics were consistently linked to increased pneumonia-related hospitalisation, recurrence, and mortality, highlighting the need for close infection monitoring in patients receiving these agents.

05 Mar 2026·Modern Rheumatology

Comparative effectiveness and safety of peficitinib and abatacept for rheumatoid arthritis: a multicentre, inverse probability weighting analysis

Article

Author: Nagaoka, Shouhei ; Nakajima, Hideaki ; Hamada, Naoki ; Yoshioka, Yuji ; Iizuka, Yuki ; Yoshimi, Ryusuke ; Shinoda, Satoru ; Ichikawa, Kento ; Ohno, Shigeru ; Nakano, Hiroto ; Sato, Yuichiro ; Hirahara, Lisa ; Maeda, Ayaka ; Hidekawa, Chiharu ; Uzawa, Yuji ; Ohno, Eriko ; Okubo, Tadanobu ; Harita, Kayo ; Sakurai, Natsuki ; Kirino, Yohei ; Takase-Minegishi, Kaoru ; Higashitani, Kana ; Kunishita, Yosuke ; Komiya, Takaaki ; Tsuchida, Naomi ; Suzuki, Naoki ; Mitsuhashi, Masaki ; Honda, Chikara ; Soejima, Yutaro ; Kishimoto, Daiga

ABSTRACT:

Objectives:

To examine the real-world effectiveness and safety of peficitinib (PEF) and abatacept (ABT) in patients with rheumatoid arthritis (RA).

Methods:

In this multicentre, retrospective cohort study, we examined patients who were administered PEF or ABT between July 2019 and July 2022. The primary endpoint was the 1-year retention rate of PEF or ABT. The primary analyses were performed using treatment persistence, disease activity measurements, and safety parameters. The inverse probability of treatment weighting (IPTW) was used to adjust for confounding variables.

Results:

A total of 219 patients were enrolled, with 64 receiving PEF and 155 receiving ABT. The 1-year retention rates were 42.8% in the PEF group and 61.0% in the ABT group after IPTW (P = .0083). Two years following the initiation of treatment, the composite disease activity measures showed comparable improvement in both groups after IPTW. Treatment discontinuation occurred primarily because of an inadequate therapeutic response (PEF: 41.3%, ABT: 28.1%) and adverse reactions (PEF: 11.1%, ABT: 3.8%).

Conclusions:

PEF treatment resulted in lower retention rates compared with ABT, whereas both medications demonstrated effectiveness in controlling disease activity for patients who were able to continue treatment. Our findings contribute to informed decision-making in RA treatment in actual clinical practice.

News (Medical) associated with Abatacept

20 Feb 2026

·www.businesswire.com

Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the US Food and Drug Administration (USFDA) has accepted for review, its 351 (k) Biologics License Application (BLA) IV for infusion formulation for DRL_AB, a proposed interchangeable biosimilar to ORENCIA® (abatacept) that was submitted in December 2025. "We are proud to be the first to submit a BLA for an abatacept biosimilar which marks a significant milestone in our mission to increase patient access to critical, high-quality biologic therapies," said Milan Kalawadia, CEO, North America, at Dr. Reddy’s. “We look forward to working with the FDA to bring this in-house developed biosimilar to market as a cost-effective alternative for patients and healthcare providers in the United States." DRL_AB, once approved will be administered as an IV for infusion formulation for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA), adults with active psoriatic arthritis (PsA), and individuals aged six years and above with moderately-to-severely active polyarticular juvenile idiopathic arthritis (pJIA). The 351 (k) BLA submission includes a comprehensive data package consisting of analytical, pharmacokinetic (PK), and clinical studies. DRL_AB Clinical Milestones: Phase 1 study (AB-01-003), achieved Pharmacokinetic similarity with comparable safety and immunogenicity profiles with Orencia. Pivotal Phase 3 study (AB-01-004), to compare the efficacy and safety of DRL_AB with Orencia [ongoing]. About DRL_AB DRL_AB is a proposed biosimilar to Orencia® (abatacept) IV for infusion, a selective co-stimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. Activated T lymphocytes are implicated in the pathogenesis of RA, pJIA and PsA and are found in the synovium of patients with RA, pJIA and PsA. References: Orencia® (abatacept) Prescribing Information https://packageinserts.bms.com/pi/pi_orencia.pdf* *Dr. Reddy’s DRL_AB is not currently seeking approval for prophylactic treatment of aGVHD. The reference product, Orencia® (abatacept), is a registered trademark owned by Bristol-Myers Squibb Company. RDY-0226-BIO About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait,’ we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Over the last 25 years, our Biologics team has developed into a fully integrated organization with robust capabilities in the development, manufacture and commercialization of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across developed as well as emerging markets. We are also ramping up manufacturing capacity to support our global expansion plans. In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner. We also launched our rituximab biosimilar in Europe in 2025. Our biosimilars business has a key role to play in driving both near-term and long-term growth. For more information, log on to: www.drreddys.com. Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.

Clinical ResultPhase 3NDAPhase 1Biosimilar

28 Jan 2026

·www.biopharmadive.com

Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

The federal government announced the next 15 medicines for which it will seek price reductions with the help of Medicares new negotiating power, including the breast cancer drugs Kisqali and Verzenio and the HIV treatment Biktarvy. Those cuts, which are allowed through the Inflation Reduction Act, will go into effect in 2028.Also included in the third annual round of price negotiations were the rheumatoid arthritis medicines Orencia, Cimzia and Xeljanz, as well as Botox when its used for therapeutic purposes like migraines. The Centers for Medicare and Medicaid Services designated these drugs for price negotiations under IRA provisions meant to limit expenditures on the drugs associated with the programs highest costs.Combined, the 15 drugs account for $27 billion in Medicare spending and are used by some 1.8 million enrollees. Eli Lillys weekly GLP-1 shot for diabetes, Trulicity, is associated with $4.9 billion in annual costs, the highest of any medication on the list.CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients not special interests, said CMS Administrator Mehmet Oz, in a statement. This approach delivers real savings while strengthening accountability across the program.For the first time, these negotiations will include medicines covered by its Part B program that involves drugs administered in a physicians office or other healthcare facility. Orencia, Cimzia and Botox are three examples.However, two key drugs that had been previously been expected to make this years list the widely used cancer immunotherapies Keytruda and Opdivo were left off. The inclusion of both was delayed by at least a year through provisions of the One Big Beautiful Bill Act, which changed the way the IRA program is applied to certain drugs.The price cuts will, as a result, be immaterial for most of the companies whose drugs are on the list, according to Leerink Partners analyst David Risinger. The one exception is Biktarvy, which has Medicare revenue that could represent 8% of Gilead Sciences 2027 sales, Risinger wrote in a note to clients.The exposure for all of the other companies involved comes to 3% or less of overall revenue, Risinger wrote.Nonetheless, the industry group Pharmaceutical Research and Manufacturers of America railed against the announcement. The group argued that the IRA is undermining future medical progress by discouraging investment in new drugs, particularly the chemical, or small molecule, drugs that are subject to IRA price negotiations sooner than biologic medications.CMS is now planning to set prices for additional small molecule cancer treatments that would otherwise be spared without this penalty driving even more investment away from these critical treatment options, said Elizabeth Carpenter, the groups executive vice president of policy and research, in a statement.The first round of price negotiations, conducted in 2024,took effect this year. '

Immunotherapy

23 Jan 2026

·www.drugs.com

One Year of Abatacept Delays Progression to RA for Up to Four Years in At-Risk Population

FRIDAY, Jan. 23, 2026 -- One-year treatment with abatacept delays progression to rheumatoid arthritis for up to four years among at-risk patients, according to a study published online Jan. 20 in The Lancet Rheumatology . Andrew P. Cope, M.D., from King's College London, and colleagues recruited 213 anticitrullinated protein antibody-positive individuals with arthralgia to a phase 2b randomized controlled trial (the Arthritis Prevention In the Preclinical Phase of Rheumatoid arthritis with Abatacept [APIPPRA]). Participants were randomly assigned to receive 52 weekly subcutaneous injections of 125 mg abatacept or placebo (110 and 103 patients, respectively), with 52 weeks of follow-up. Follow-up was extended to between four and eight years in the APIPPRA Long-Term Outcome (ALTO) study; 143 APIPPRA participants were enrolled in ALTO: 71 and 72 in the abatacept and placebo groups, respectively. The researchers observed an increase of 54 primary events to 119. The initial between-group difference in restricted mean arthritis-free survival time, which was observed at two years, persisted at four years (4.9 months); over time, the magnitude of the difference diminished. No significant between-group differences were seen in assessments of disease activity and patient-reported outcomes beyond the treatment period. Participants with a broad autoantibody profile at baseline had the highest risk for progressing, but they had better response to abatacept. "We have shown that this approach is safe and can prevent disease while patients are on treatment as well as substantially relieve symptoms," Cope said in a statement. "Importantly, it can also delay the onset of RA for several years, even after treatment has stopped." Several authors disclosed ties to biopharmaceutical companies, including Bristol Myers Squibb, which manufactures abatacept and funded the study. Abstract/Full Text Editorial (subscription or payment may be required)

Phase 2Clinical Result

100 Deals associated with Abatacept

External Link

KEGG	Wiki	ATC	Drug Bank
D03203	Abatacept	L04AA24	DB01281

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Graft Versus Host Disease	United States	Bristol Myers Squibb Co.	15 Dec 2021
Juvenile Idiopathic Arthritis	United States	Bristol Myers Squibb Co.	25 Aug 2009
Arthritis, Psoriatic	European Union	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Arthritis, Psoriatic	Iceland	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Arthritis, Psoriatic	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Arthritis, Psoriatic	Norway	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Polyarticular Juvenile Idiopathic Arthritis	European Union	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Polyarticular Juvenile Idiopathic Arthritis	Iceland	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Polyarticular Juvenile Idiopathic Arthritis	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Polyarticular Juvenile Idiopathic Arthritis	Norway	Bristol-Myers Squibb Pharma EEIG	21 May 2007
Rheumatoid Arthritis	United States	Bristol Myers Squibb Co.	23 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myocarditis	Phase 3	United States	Bristol Myers Squibb Co.	02 Jul 2022
Myocarditis	Phase 3	Canada	Bristol Myers Squibb Co.	02 Jul 2022
Polymyalgia Rheumatica	Phase 3	France	Bristol Myers Squibb Co.	13 Dec 2018
Osteitis	Phase 3	Czechia	Bristol Myers Squibb Co.	06 Dec 2018
Tenosynovitis	Phase 3	Czechia	Bristol Myers Squibb Co.	06 Dec 2018
Giant Cell Arteritis	Phase 3	United States	Bristol Myers Squibb Co.	15 Jul 2017
Giant Cell Arteritis	Phase 3	Australia	Bristol Myers Squibb Co.	15 Jul 2017
Giant Cell Arteritis	Phase 3	Austria	Bristol Myers Squibb Co.	15 Jul 2017
Giant Cell Arteritis	Phase 3	Belgium	Bristol Myers Squibb Co.	15 Jul 2017
Giant Cell Arteritis	Phase 3	Bulgaria	Bristol Myers Squibb Co.	15 Jul 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2026	Phase 1/2	Graft vs Host Disease	57	Post-transplant cyclophosphamide 50mg/kg (Full dose PTC)	xzjjwymbov(blsosrumwr) = 1 patient developed PTLD, responsive to rituximab rcgokvyrbm (gzfawtlgqt ) View more	Positive	04 Feb 2026
				Post-transplant cyclophosphamide 37.5mg/kg (Reduced dose PTC)
NCT03924401 (ASCENT, Tandem Meetings ASTCT and CIBMTR2026)	Phase 1	Acute Graft Versus Host Disease	30	Abatacept 10 mg/kg IV	ribqunzbmy(guuldwebnu) = djpvtdcyci qrgsmyraxr (nooevjiwtr ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Acute Graft Versus Host Disease	5	Abatacept + Tacrolimus + MTX	rnxvtpgcsp(vhpqoebzte) = gxrrurvspo zxbtiivzel (zsuxenhqhe ) View more	Negative	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Graft vs Host Disease	73	PTCY, Abatacept, Tacrolimus	qylqsqrspf(cqnrvhxmxx) = fycjsxtlpt winshvpwce (gsgcbjrwku, 50.5 - 73.9) View more	Positive	04 Feb 2026
ASH2025	Not Applicable	Hematologic Neoplasms	99	Abatacept + Post-transplant Cyclophosphamide + Tacrolimus	pcgjuannpy(uwnmpoyqzk) = zpovvbrnmx durzbturlq (zfbvahbafh ) View more	Positive	06 Dec 2025
				Mycophenolate + Post-transplant Cyclophosphamide + Tacrolimus	pcgjuannpy(uwnmpoyqzk) = agokqbzeyd durzbturlq (zfbvahbafh ) View more
ASH2025	Not Applicable	Hematologic Neoplasms	2,683	conventional GVHD prophylaxis + immunosuppressive agent	gdropwerkx(psvjxtkdoq) = blkcglklja wzwqyiqgbi (ixqppfxtmg, 0.95 - 1.31) View more	Positive	06 Dec 2025
				conventional GVHD prophylaxis	-
EUCTR2014-000555-93-CZ (ARIAA, ACR2025)	Phase 3	ACPA-positive	98	Abatacept 125 mg sc weekly	bqeefzptgt(lnwaoplupu) = spdevdwheq rmpbpthuhh (hemlmaoerm ) View more	Positive	24 Oct 2025
				Placebo	bqeefzptgt(lnwaoplupu) = anmtracngp rmpbpthuhh (hemlmaoerm ) View more
NORD-STAR (ACR2025)	Not Applicable	-	624	Methotrexate combined with other csDMARDs/corticosteroids or steroids alone	erwelwvyjv(rrramdaron) = nkjhjspaby filbsmrobm (zyyrqrbhxo ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Rheumatoid arthritis with rheumatoid lung disease	526	Abatacept (Progressive ILD)	ekuuqcclmt(nttyviwvrr) = pyropiopim dhbhriaaax (pdapzedkiu ) View more	Positive	24 Oct 2025
NCT04120831 (ALTO, ACR2025)	Phase 3	Arthralgia	143	Abatacept	lhhizpnhfr(ohutounkyc) = bcauavfnwa fgurnomanc (orzoigviij ) View more	Positive	24 Oct 2025
				Placebo	lhhizpnhfr(ohutounkyc) = yxdejatltb fgurnomanc (orzoigviij ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis